111 related articles for article (PubMed ID: 19536865)
21. Cathepsin K mRNA and protein expression in prostate cancer progression.
Brubaker KD; Vessella RL; True LD; Thomas R; Corey E
J Bone Miner Res; 2003 Feb; 18(2):222-30. PubMed ID: 12568399
[TBL] [Abstract][Full Text] [Related]
22. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
[TBL] [Abstract][Full Text] [Related]
23. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
24. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.
Kauffman EC; Robinson VL; Stadler WM; Sokoloff MH; Rinker-Schaeffer CW
J Urol; 2003 Mar; 169(3):1122-33. PubMed ID: 12576866
[TBL] [Abstract][Full Text] [Related]
25. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
McCarty MF
Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer.
Montano X; Djamgoz MB
FEBS Lett; 2004 Jul; 571(1-3):1-8. PubMed ID: 15280008
[TBL] [Abstract][Full Text] [Related]
27. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
28. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
Langer F; Chun FK; Amirkhosravi A; Friedrich M; Leuenroth S; Eifrig B; Bokemeyer C; Francis JL
Thromb Haemost; 2007 Mar; 97(3):464-70. PubMed ID: 17334515
[TBL] [Abstract][Full Text] [Related]
29. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
[TBL] [Abstract][Full Text] [Related]
30. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
31. Prognostic markers in clinically localized prostate cancer.
Pettaway CA
Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
[TBL] [Abstract][Full Text] [Related]
32. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
34. Serum markers for prostate cancer: a rational approach to the literature.
Steuber T; O'Brien MF; Lilja H
Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
[TBL] [Abstract][Full Text] [Related]
35. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.
Nelson JB; Chan-Tack K; Hedican SP; Magnuson SR; Opgenorth TJ; Bova GS; Simons JW
Cancer Res; 1996 Feb; 56(4):663-8. PubMed ID: 8630991
[TBL] [Abstract][Full Text] [Related]
36. Role of Wnts in prostate cancer bone metastases.
Hall CL; Kang S; MacDougald OA; Keller ET
J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163
[TBL] [Abstract][Full Text] [Related]
37. New concepts in the treatment of stage D1 adenocarcinoma of the prostate.
Austenfeld MS; Davis BE
Urol Clin North Am; 1990 Nov; 17(4):867-84. PubMed ID: 2219583
[TBL] [Abstract][Full Text] [Related]
38. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer.
Lam YW; Mobley JA; Evans JE; Carmody JF; Ho SM
Proteomics; 2005 Jul; 5(11):2927-38. PubMed ID: 15952230
[TBL] [Abstract][Full Text] [Related]
39. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model.
Duan W; Gabril MY; Moussa M; Chan FL; Sakai H; Fong G; Xuan JW
Oncogene; 2005 Feb; 24(9):1510-24. PubMed ID: 15674347
[TBL] [Abstract][Full Text] [Related]
40. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
